-
PORACTANT ALFA VERSUS CALFACTANT FOR NEONATAL RESPIRATORY DISTRESS SYNDROME: A MULTICENTER COST-EFFECTIVENESS STUDY
Aug 11, 2026, 17:16 PM -
HEALTH AND ECONOMIC IMPACT OF CATCH-UP RSV MAB IMMUNIZATION IN INFANTS IN GREECE
Aug 11, 2026, 17:16 PM -
SIMULATED COST IMPACT OF TRABECULAR MICRO-BYPASS IN A FIXED COHORT OF 55,000 PATIENTS UNDERGOING CATARACT SURGERY
Aug 11, 2026, 17:16 PM -
PEDIATRIC LIVER TRANSPLANTATION IN THE BRAZILIAN UNIFIED HEALTH SYSTEM (SUS): REAL-WORLD RESOURCE UTILIZATION AND CLINICAL OUTCOMES (2015-2025)
Aug 11, 2026, 17:16 PM -
DRIVERS OF NICE ACCEPTANCE FOR HIGH ICER VALUES: A COMPARATIVE ANALYSIS OF TECHNOLOGY APPRAISALS (TA)
Aug 11, 2026, 17:16 PM -
RELATIONSHIP BETWEEN LOWER LIMB FUNCTIONAL PARAMETERS, PHYSICAL PERFORMANCE AND INJURY RISK INDICATORS IN U9-U13 ATHLETES
Aug 11, 2026, 17:16 PM -
TRANSFORMING PRE-LAUNCH FORECASTING: AN AGENTIC AI PLATFORM FOR TRANSPARENT SCENARIO PLANNING IN PHARMA
Aug 11, 2026, 17:16 PM -
IMPROVING ASTHMA OUTCOMES WHILE REDUCING COSTS: A VALUE-DRIVEN CARE PATHWAY AT A SINGAPORE TERTIARY HOSPITAL
Aug 11, 2026, 17:16 PM -
COST-EFFECTIVE INTERVENTIONS TO PREVENT ADOLESCENT SELF-HARM AND SUICIDE: A SYSTEMATIC REVIEW
Aug 11, 2026, 17:16 PM -
CGVHD HEALTHCARE PATHWAY, UNMET NEED AND ECONOMIC BURDEN IN ALGERIA: A FIRST PHARMACOECONOMIC STUDY
Aug 11, 2026, 17:16 PM -
IS EUROPE BECOMING A LATER REGULATORY LAUNCH MARKET? TRENDS IN EMA AUTHORISATION AFTER FDA APPROVAL
Aug 11, 2026, 17:16 PM -
NOT A SUBMISSION, A SYSTEM: JOINT CLINICAL ASSESSMENT AS AN ENTERPRISE CAPABILITY
Aug 11, 2026, 17:16 PM -
AN AGENTIC AI MODEL VALIDATOR FOR AUTOMATED QUALITY CHECK OF EXCEL-BASED BUDGET IMPACT MODELS
Aug 11, 2026, 17:16 PM -
ARTIFICIAL INTELLIGENCE IN HEALTH TECHNOLOGY ASSESSMENT: A LANDSCAPE REVIEW OF OPPORTUNITIES, CHALLENGES, AND STAKEHOLDER RESPONSIBILITIES
Aug 11, 2026, 17:16 PM -
RELAPSE AND ASSOCIATED HEALTHCARE BURDEN IN POLYMYALGIA RHEUMATICA (PMR) AND GIANT CELL ARTERITIS (GCA): A RETROSPECTIVE COHORT STUDY IN GERMANY
Aug 11, 2026, 17:16 PM -
ECONOMIC BURDEN OF IMMUNE-RELATED ADVERSE EVENTS OF IMMUNE CHECKPOINT INHIBITORS FROM PAYER PERSPECTIVE. A REAL-WORLD PATIENT-LEVEL MICRO-COSTING STUDY FROM QATAR
Aug 11, 2026, 17:16 PM -
RANKING OF TREATMENTS IN MULTI-LEVEL NETWORK META-REGRESSION (ML-NMR): INCORPORATING MINIMALLY IMPORTANT DIFFERENCES
Aug 11, 2026, 17:16 PM -
ARE AI-BASED DIGITAL TWINS ENTERING HTA? A REVIEW AND INSIGHT INTO AN EMERGING AND EVOLVING EVIDENCE-GENERATION APPROACH
Aug 11, 2026, 17:16 PM -
PRODUCTIVITY LOSS IN PATIENTS WITH MODERATE-TO-SEVERE THYROID EYE DISEASE IN SPAIN AND ITALY: RESULTS FROM A REAL-WORLD CROSS-SECTIONAL STUDY
Aug 11, 2026, 17:16 PM -
IMPACT OF ENDPOINT SELECTION ON COMPARATIVE EFFICACY CONCLUSIONS IN CROHN'S DISEASE (CD)
Aug 11, 2026, 17:16 PM
